TVAX ImmunotherapySM uses the natural resources of the immune system to treat cancer.
TVAX Biomedical
is performing phase II/III clinical trials to determine the
safety and efficacy of TVAX Immunotherapy in patients with astrocytomas, a type of brain cancer and
renal cell carcinomas, a type of kidney cancer.
See TVAX Technology for a description of the TVAX treatment and the underlying science.
See Outcomes - Brain for a summary of completed clinical studies pertaining to brain cancer.
See Outcomes - Kidney for a summary of completed clinical studies pertaining to kidney cancer.
|
|